Trial Profile
A Randomized Phase III trial of an Endostatin Gene therapy (E10A) combined with chemotherapy and chemotherapy alone for the treatment of head and neck cancer
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2015
Price :
$35
*
At a glance
- Drugs Endostatin gene therapy (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 12 Dec 2015 According to a media release of Marsala Biotech Inc. this trial completed Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the treatment of head and neck cancer.
- 30 Nov 2015 New trial record